Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: VRDN) | Delayed: 22.37 -0.45 (1.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $22.82 | 52 Week High | $ | |||
| Open | $22.75 | 52 Week Low | $ | |||
| Day High | $22.75 | P/E | N/A | |||
| Day Low | $21.92 | EPS | $ | |||
| Volume | 1,179,022 | |||||
